At a glance
- Originator Cardiome Pharma; Rhythm Search Developments
- Developer Cardiome Pharma; Rhythm Search Developments; University of British Columbia
- Class Class I antiarrhythmics
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 27 May 2020 Correvio Pharma has been acquired by ADVANZ PHARMA
- 15 May 2018 Cardiome Pharma is now called Correvio Pharma
- 27 Mar 2003 Discontinued - Preclinical for Arrhythmias in Canada (unspecified route)